<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28969658</PMID><DateCompleted><Year>2018</Year><Month>05</Month><Day>29</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1743-422X</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2017</Year><Month>Oct</Month><Day>02</Day></PubDate></JournalIssue><Title>Virology journal</Title><ISOAbbreviation>Virol J</ISOAbbreviation></Journal><ArticleTitle>Characterization and epitope mapping of Dengue virus type 1 specific monoclonal antibodies.</ArticleTitle><Pagination><StartPage>189</StartPage><MedlinePgn>189</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">189</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12985-017-0856-8</ELocationID><Abstract><AbstractText Label="BACKGROUND">Dengue virus (DV) infection causes a spectrum of clinical diseases ranging from dengue fever to a life-threatening dengue hemorrhagic fever. Four distinct serotypes (DV1-4), which have similar genome sequences and envelope protein (E protein) antigenic properties, were divided. Among these 4 serotypes, DV1 usually causes predominant infections and fast diagnosis and effective treatments are urgently required to prevent further hospitalization and casualties.</AbstractText><AbstractText Label="METHODS">To develop antibodies specifically targeting and neutralizing DV1, we immunized mice with UV-inactivated DV1 viral particles and recombinant DV1 E protein from residue 1 to 395 (E395), and then generated 12 anti-E monoclonal antibodies (mAbs) as the candidates for a series of characterized assays such as ELISA, dot blot, immunofluorescence assay, western blot, and foci forming analyses.</AbstractText><AbstractText Label="RESULTS">Among the mAbs, 10 out of 12 showed cross-reactivity to four DV serotypes as well as Japanese encephalitis virus (JEV) in different cross-reactivity patterns. Two particular mAbs, DV1-E1 and DV1-E2, exhibited strong binding specificity and neutralizing activity against DV1 and showed no cross-reactivity to DV2, DV3, DV4 or JEV-infected cells as characterized by ELISA, dot blot, immunofluorescence assay, western blot, and foci forming analyses. Using peptide coated indirect ELISA, we localized the neutralizing determinants of the strongly inhibitory mAbs to a sequence-unique epitope on the later-ridge of domain III of the DV1 E protein, centered near residues T346 and D360 (<sup>346</sup>TQNGRLITANPIVTD<sup>360</sup>). Interestingly, the amino acid sequence of the epitope region is highly conserved among different genotypes of DV1 but diverse from DV2, DV3, DV4 serotypes and other flaviviruses.</AbstractText><AbstractText Label="CONCLUSIONS">Our results showed two selected mAbs DV1-E1 and DV1-E2 can specifically target and significantly neutralize DV1. With further research these two mAbs might be applied in the development of DV1 specific serologic diagnosis and used as a feasible treatment option for DV1 infection. The identification of DV1 mAbs epitope with key residues can also provide vital information for vaccine design.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Wen-Hung</ForeName><Initials>WH</Initials><AffiliationInfo><Affiliation>Department of Biological Science and Technology, National Chiao Tung University, Hsin-Chu, 30068, Taiwan, Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chou</LastName><ForeName>Feng-Pai</ForeName><Initials>FP</Initials><AffiliationInfo><Affiliation>Department of Biological Science and Technology, National Chiao Tung University, Hsin-Chu, 30068, Taiwan, Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yu-Kuo</ForeName><Initials>YK</Initials><AffiliationInfo><Affiliation>Department of Biological Science and Technology, National Chiao Tung University, Hsin-Chu, 30068, Taiwan, Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Sheng-Cih</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Department of Biological Science and Technology, National Chiao Tung University, Hsin-Chu, 30068, Taiwan, Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Chuan-Hung</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Department of Biological Science and Technology, National Chiao Tung University, Hsin-Chu, 30068, Taiwan, Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Tung-Kung</ForeName><Initials>TK</Initials><Identifier Source="ORCID">0000-0002-6478-7768</Identifier><AffiliationInfo><Affiliation>Department of Biological Science and Technology, National Chiao Tung University, Hsin-Chu, 30068, Taiwan, Republic of China. tkwmll@mail.nctu.edu.tw.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>10</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Virol J</MedlineTA><NlmUniqueID>101231645</NlmUniqueID><ISSNLinking>1743-422X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007155">Immunologic Factors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003716" MajorTopicYN="N">Dengue Virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018604" MajorTopicYN="Y">Epitope Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007118" MajorTopicYN="N">Immunoassay</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007155" MajorTopicYN="N">Immunologic Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Dengue virus (DV)</Keyword><Keyword MajorTopicYN="N">Envelope protein</Keyword><Keyword MajorTopicYN="N">Epitope</Keyword><Keyword MajorTopicYN="N">Monoclonal antibody</Keyword></KeywordList><CoiStatement>ETHICS APPROVAL AND CONSENT TO PARTICIPATE: Procedures were reviewed and approved by the Committee of Laboratory Animal Care and Use, NCTU, and the experimental operations are strictly followed &#x201c;Guide for the Care and Use of Laboratory Animals&#x201d;, Laboratory Animal Center, NCTU. CONSENT FOR PUBLICATION: Not applicable. COMPETING INTERESTS: The authors declare that they have no competing interests. PUBLISHER&#x2019;S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>7</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>9</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>10</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>10</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>5</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28969658</ArticleId><ArticleId IdType="pmc">PMC5625772</ArticleId><ArticleId IdType="doi">10.1186/s12985-017-0856-8</ArticleId><ArticleId IdType="pii">10.1186/s12985-017-0856-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Burke DS, Monath TP. Flaviviruses. In: Knipe DM, Howley PM, editors. Fields Virology. Philadelphia: Lippincott Williams &amp; Wilkins; 2001. pp. 1043&#x2013;1126.</Citation></Reference><Reference><Citation>Guzm&#xe1;n MG, Kour&#xed; G. Dengue: an update. Lancet Infect Dis. 2002;2:33&#x2013;42. doi: 10.1016/S1473-3099(01)00171-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(01)00171-2</ArticleId><ArticleId IdType="pubmed">11892494</ArticleId></ArticleIdList></Reference><Reference><Citation>Imrie A, Meeks J, Gurary A, Sukhbaatar M, Truong TT, Cropp CB, Effler P. Antibody to dengue 1 detected more than 60 years after infection. Viral Immunol. 2007;20:672&#x2013;675. doi: 10.1089/vim.2007.0050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/vim.2007.0050</ArticleId><ArticleId IdType="pmc">PMC3084288</ArticleId><ArticleId IdType="pubmed">18158740</ArticleId></ArticleIdList></Reference><Reference><Citation>Gubler DJ. Dengue/dengue haemorrhagic fever: history and current status. Novartis Found Symp. 2006;277:3&#x2013;16. doi: 10.1002/0470058005.ch2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/0470058005.ch2</ArticleId><ArticleId IdType="pubmed">17319151</ArticleId></ArticleIdList></Reference><Reference><Citation>Halstead SB. Neutralization and antibody-dependent enhancement of dengue viruses. Adv Virus Res. 2003;60:421&#x2013;467. doi: 10.1016/S0065-3527(03)60011-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0065-3527(03)60011-4</ArticleId><ArticleId IdType="pubmed">14689700</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. Dengue vaccine: WHO position paper &#x2013;. 2016;91:349&#x2013;364. http://www.who.int/wer/2016/wer9130.pdf?ua=1. Accessed 29 July 2016.</Citation></Reference><Reference><Citation>Halstead SB. Pathogenesis of dengue: challenges to molecular biology. Science. 1998;239:476&#x2013;481. doi: 10.1126/science.3277268.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.3277268</ArticleId><ArticleId IdType="pubmed">3277268</ArticleId></ArticleIdList></Reference><Reference><Citation>Guy B, Jackson N. Dengue vaccine: hypotheses to understand CYD-TDV- induced protection. Nat Rev Microbiol. 2016;14:45&#x2013;54. doi: 10.1038/nrmicro.2015.2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrmicro.2015.2</ArticleId><ArticleId IdType="pubmed">26639777</ArticleId></ArticleIdList></Reference><Reference><Citation>Chuang TW, Chaves LF, Chen PJ. Effects of local and regional climatic fluctuations on dengue outbreaks in southern Taiwan. PLoS One. 2017;12:e0178698. doi: 10.1371/journal.pone.0178698.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0178698</ArticleId><ArticleId IdType="pmc">PMC5456348</ArticleId><ArticleId IdType="pubmed">28575035</ArticleId></ArticleIdList></Reference><Reference><Citation>Chambers TJ, Hahn CS, Galler R, Rice CM. Flavivirus genome organization, expression, and replication. Annu Rev Microbiol. 1990;44:649&#x2013;688. doi: 10.1146/annurev.mi.44.100190.003245.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.mi.44.100190.003245</ArticleId><ArticleId IdType="pubmed">2174669</ArticleId></ArticleIdList></Reference><Reference><Citation>Deubel V, Kinney RM, Trent DW. Nucleotide sequence and deduced amino acid sequence of the nonstructural proteins of dengue type 2 virus, Jamaica genotype: comparative analysis of the full-length genome. Virology. 1988;165:234&#x2013;244. doi: 10.1016/0042-6822(88)90677-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0042-6822(88)90677-0</ArticleId><ArticleId IdType="pubmed">3388770</ArticleId></ArticleIdList></Reference><Reference><Citation>Henchal EA, Putnak JR. The dengue viruses. Clin Microbiol Rev. 1990;3:376&#x2013;396. doi: 10.1128/CMR.3.4.376.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CMR.3.4.376</ArticleId><ArticleId IdType="pmc">PMC358169</ArticleId><ArticleId IdType="pubmed">2224837</ArticleId></ArticleIdList></Reference><Reference><Citation>Roehrig JT. Antigenic structure of flavivirus proteins. Adv Virus Res. 2003;59:141&#x2013;175. doi: 10.1016/S0065-3527(03)59005-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0065-3527(03)59005-4</ArticleId><ArticleId IdType="pubmed">14696329</ArticleId></ArticleIdList></Reference><Reference><Citation>Pierson TC, Fremont DH, Kuhn RJK, Diamond MS. Structural insights into the mechanisms of antibody-mediated neutralization of flavivirus infection: implications for vaccine development. Cell Host Microbe. 2008;4:229&#x2013;238. doi: 10.1016/j.chom.2008.08.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2008.08.004</ArticleId><ArticleId IdType="pmc">PMC2678546</ArticleId><ArticleId IdType="pubmed">18779049</ArticleId></ArticleIdList></Reference><Reference><Citation>Modis Y, Ogata S, Clements D, Harrison SC. A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc Natl Acad Sci U S A. 2003;100:6986&#x2013;6991. doi: 10.1073/pnas.0832193100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0832193100</ArticleId><ArticleId IdType="pmc">PMC165817</ArticleId><ArticleId IdType="pubmed">12759475</ArticleId></ArticleIdList></Reference><Reference><Citation>Modis Y, Ogata S, Clements D, Harrison SC. Structure of the dengue virus envelope protein after membrane fusion. Nature. 2004;427:313&#x2013;319. doi: 10.1038/nature02165.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature02165</ArticleId><ArticleId IdType="pubmed">14737159</ArticleId></ArticleIdList></Reference><Reference><Citation>Modis Y, Ogata S, Clements D, Harrison SC. Variable surface epitopes in the crystal structure of dengue virus type 3 envelope glycoprotein. J Virol. 2005;79:1223&#x2013;1231. doi: 10.1128/JVI.79.2.1223-1231.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.79.2.1223-1231.2005</ArticleId><ArticleId IdType="pmc">PMC538574</ArticleId><ArticleId IdType="pubmed">15613349</ArticleId></ArticleIdList></Reference><Reference><Citation>Nayak V, Dessau M, Kucera K, Anthony K, Ledizet M, Modis Y. Crystal structure of dengue virus type 1 envelope protein in the postfusion conformation and its implications for membrane fusion. J Virol. 2009;83:4338&#x2013;4344. doi: 10.1128/JVI.02574-08.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02574-08</ArticleId><ArticleId IdType="pmc">PMC2668458</ArticleId><ArticleId IdType="pubmed">19244332</ArticleId></ArticleIdList></Reference><Reference><Citation>Crill WD, Roehrig JT. Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. J Virol. 2001;75:7769&#x2013;7773. doi: 10.1128/JVI.75.16.7769-7773.2001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.75.16.7769-7773.2001</ArticleId><ArticleId IdType="pmc">PMC115016</ArticleId><ArticleId IdType="pubmed">11462053</ArticleId></ArticleIdList></Reference><Reference><Citation>Stiasny K, Kiermayr S, Holzmann H, Heinz FX. Cryptic properties of a cluster of dominant flavivirus cross-reactive antigenic sites. J Virol. 2006;80:9557&#x2013;9568. doi: 10.1128/JVI.00080-06.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00080-06</ArticleId><ArticleId IdType="pmc">PMC1617264</ArticleId><ArticleId IdType="pubmed">16973559</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai CY, Tsai WY, Lin SR, Kao CL, Hu HP, King CC, Wu HC, Chang GJ, Wang WK. Antibodies to envelope glycoprotein of dengue virus during the natural course of infection are predominantly cross-reactive and recognize epitopes containing highly conserved residues at the fusion loop of domain II. J Virol. 2008;82:6631&#x2013;6643. doi: 10.1128/JVI.00316-08.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00316-08</ArticleId><ArticleId IdType="pmc">PMC2447043</ArticleId><ArticleId IdType="pubmed">18448542</ArticleId></ArticleIdList></Reference><Reference><Citation>Crill WD, Hughes HR, Delorey MJ, Chang GJ. Humoral immune responses of dengue fever patients using epitope-specific serotype-2 virus-like particle antigens. PLoS One. 2009;4:e4991. doi: 10.1371/journal.pone.0004991.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0004991</ArticleId><ArticleId IdType="pmc">PMC2659788</ArticleId><ArticleId IdType="pubmed">19337372</ArticleId></ArticleIdList></Reference><Reference><Citation>Dejnirattisai W, Jumnainsong A, Onsirisakul N, Fitton P, Vasanawathana S, Limpitikul W, Puttikhunt C, Edwards C, Duangchinda T, Supasa S, Chawansuntati K, Malasit P, Mongkolsapaya J, Screaton G. Cross-reacting antibodies enhance dengue virus infection in humans. Science. 2010;328:745&#x2013;748. doi: 10.1126/science.1185181.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1185181</ArticleId><ArticleId IdType="pmc">PMC3837288</ArticleId><ArticleId IdType="pubmed">20448183</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahala WM, Kraus AA, Haymore LB, Accavitti-Loper MA, de Silva AM. Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody. Virology. 2009;392:103&#x2013;113. doi: 10.1016/j.virol.2009.06.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2009.06.037</ArticleId><ArticleId IdType="pmc">PMC2746956</ArticleId><ArticleId IdType="pubmed">19631955</ArticleId></ArticleIdList></Reference><Reference><Citation>Beltramello M, Williams KL, Simmons CP, Macagno A, Simonelli L, Quyen NT, Sukupolvi-Petty S, Navarro-Sanchez E, Young PR, de Silva AM, Rey FA, Varani L, Whitehead SS, Diamond MS, Harris E, Lanzavecchia A, Sallusto F. The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe. 2010;8:271&#x2013;283. doi: 10.1016/j.chom.2010.08.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2010.08.007</ArticleId><ArticleId IdType="pmc">PMC3884547</ArticleId><ArticleId IdType="pubmed">20833378</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng YQ, Dai JX, Ji GH, Jiang T, Wang HJ, Yang HO, Tan WL, Liu R, Yu M, Ge BX, Zhu QY, Qin ED, Guo YJ, Qin CF. A broadly flavivirus cross-neutralizing monoclonal antibody that recognizes a novel epitope within the fusion loop of E protein. PLoS One. 2011;6:e16059. doi: 10.1371/journal.pone.0016059.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0016059</ArticleId><ArticleId IdType="pmc">PMC3019176</ArticleId><ArticleId IdType="pubmed">21264311</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen WH, Hsu IH, Sun YC, Wang YK, Wu TK. Immunocapture couples with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for rapid detection of type 1 dengue virus. J Chromatogr A. 2013;1288:21&#x2013;27. doi: 10.1016/j.chroma.2013.02.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chroma.2013.02.030</ArticleId><ArticleId IdType="pubmed">23541657</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen YC, Huang HN, Lin CT, Chen YF, King CC, Wu HC. Generation and characterization of monoclonal antibodies against dengue virus type 1 for epitope mapping and serological detection by epitope-based peptide antigens. Clin Vaccine Immunol. 2007;14:404&#x2013;411. doi: 10.1128/CVI.00249-06.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CVI.00249-06</ArticleId><ArticleId IdType="pmc">PMC1865613</ArticleId><ArticleId IdType="pubmed">17287314</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrestha B, Brien JD, Sukupolvi-Petty S, Austin SK, Edeling MA, Kim T, O'Brien KM, Nelson CA, Johnson S, et al. The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1. PLoS Pathog. 2010;6:e1000823. doi: 10.1371/journal.ppat.1000823.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1000823</ArticleId><ArticleId IdType="pmc">PMC2848552</ArticleId><ArticleId IdType="pubmed">20369024</ArticleId></ArticleIdList></Reference><Reference><Citation>Simantini E, Banerjee K. Epitope mapping of dengue 1 virus E glycoprotein using monoclonal antibodies. Arch Virol. 1995;140:1257&#x2013;1273. doi: 10.1007/BF01322751.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF01322751</ArticleId><ArticleId IdType="pubmed">7646356</ArticleId></ArticleIdList></Reference><Reference><Citation>Cockburn JJ, Navarro Sanchez ME, Fretes N, Urvoas A, Staropoli I, Kikuti CM, Coffey LL, Arenzana Seisdedos F, Bedouelle H, Rey FA. Mechanism of dengue virus broad cross-neutralization by a monoclonal antibody. Structure. 2012;20:303&#x2013;314. doi: 10.1016/j.str.2012.01.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.str.2012.01.001</ArticleId><ArticleId IdType="pubmed">22285214</ArticleId></ArticleIdList></Reference><Reference><Citation>Cockburn JJ, Navarro Sanchez ME, Goncalvez AP, Zaitseva E, Stura EA, Kikuti CM, Duquerroy S, Dussart P, Chernomordik LV, Lai CJ, Rey FA. Structural insights into the neutralization mechanism of a higher primate antibody against dengue virus. EMBO J. 2012;31:767&#x2013;779. doi: 10.1038/emboj.2011.439.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emboj.2011.439</ArticleId><ArticleId IdType="pmc">PMC3273384</ArticleId><ArticleId IdType="pubmed">22139356</ArticleId></ArticleIdList></Reference><Reference><Citation>Fibriansah G, Tan JL, Smith SA, de Alwis AR, Ng TS, Kostyuchenko VA, Ibarra KD, Wang J, Harris E, de Silva A, Crowe JE, Jr, Lok SM. A potent anti-dengue human antibody preferentially recognizes the conformation of E protein monomers assembled on the virus surface. EMBO Mol Med. 2014;6:358&#x2013;371.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3958310</ArticleId><ArticleId IdType="pubmed">24421336</ArticleId></ArticleIdList></Reference><Reference><Citation>Sukhavachana P, Nisalak A, Halstead SB. Tissue culture techniques for the study of dengue viruses. Bull World Health Organ. 1966;35:65&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2476177</ArticleId><ArticleId IdType="pubmed">20604260</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen WL, Huang MT, Liu HC, Li CW, Mao SJ. Distinction between dry and raw milk using monoclonal antibodies prepared against dry milk proteins. J Dairy Sci. 2004;87:2720&#x2013;2729. doi: 10.3168/jds.S0022-0302(04)73399-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.3168/jds.S0022-0302(04)73399-8</ArticleId><ArticleId IdType="pubmed">15328298</ArticleId></ArticleIdList></Reference><Reference><Citation>Henchal EA, Gentry MK, McCown JM, Brandt WE. Dengue virus-specific and flavivirus group determinants identified with monoclonal antibodies by indirect immunofluorescence. Am J Trop Med Hyg. 1982;31:830&#x2013;836. doi: 10.4269/ajtmh.1982.31.830.</Citation><ArticleIdList><ArticleId IdType="doi">10.4269/ajtmh.1982.31.830</ArticleId><ArticleId IdType="pubmed">6285749</ArticleId></ArticleIdList></Reference><Reference><Citation>Aaskov JG, Geysen HM, Mason TJ. Serologically defined linear epitopes in the envelope protein of dengue 2 (Jamaica strain 1409) Arch Virol. 1989;105:209&#x2013;221. doi: 10.1007/BF01311358.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF01311358</ArticleId><ArticleId IdType="pubmed">2473720</ArticleId></ArticleIdList></Reference><Reference><Citation>Beasley DW, Barrett AD. Identification of neutralizing epitopes within structural domain III of the West Nile virus envelope protein. J Virol. 2002;76:13097&#x2013;13100. doi: 10.1128/JVI.76.24.13097-13100.2002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.76.24.13097-13100.2002</ArticleId><ArticleId IdType="pmc">PMC136710</ArticleId><ArticleId IdType="pubmed">12438639</ArticleId></ArticleIdList></Reference><Reference><Citation>Megret F, Hugnot JP, Falconar A, Gentry MK, Morens DM, Murray JM, Schlesinger JJ, Wright PJ, Young P, et al. Use of recombinant fusion proteins and monoclonal antibodies to define linear and discontinuous antigenic sites on the dengue virus envelope glycoprotein. Virology. 1992;187:480&#x2013;491. doi: 10.1016/0042-6822(92)90450-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0042-6822(92)90450-4</ArticleId><ArticleId IdType="pubmed">1372140</ArticleId></ArticleIdList></Reference><Reference><Citation>Roehrig JT, Bolin RA, Kelly RG. Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica. Virology. 1998;246:317&#x2013;328. doi: 10.1006/viro.1998.9200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/viro.1998.9200</ArticleId><ArticleId IdType="pubmed">9657950</ArticleId></ArticleIdList></Reference><Reference><Citation>Sukupolvi-Petty S, Austin SK, Purtha WE, Oliphant T, Nybakken GE, Schlesinger JJ, Roehrig JT, Gromowski GD, Barrett AD, et al. Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. J Virol. 2007;81:12816&#x2013;12826. doi: 10.1128/JVI.00432-07.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00432-07</ArticleId><ArticleId IdType="pmc">PMC2169112</ArticleId><ArticleId IdType="pubmed">17881453</ArticleId></ArticleIdList></Reference><Reference><Citation>Thullier P, Demangel C, Bedouelle H, Megret F, Jouan A, Deubel V, Mazie JC, Lafaye P. Mapping of a dengue virus neutralizing epitope critical for the infectivity of all serotypes: insight into the neutralization mechanism. J Gen Virol. 2001;82:1885&#x2013;1892. doi: 10.1099/0022-1317-82-8-1885.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/0022-1317-82-8-1885</ArticleId><ArticleId IdType="pubmed">11457994</ArticleId></ArticleIdList></Reference><Reference><Citation>de Alwis R, Smith SA, Olivarez NP, Messer WB, Huynh JP, Wahala WM, White LJ, Diamond MS, Baric RS, et al. Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc Natl Acad Sci U S A. 2012;109:7439&#x2013;7444. doi: 10.1073/pnas.1200566109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1200566109</ArticleId><ArticleId IdType="pmc">PMC3358852</ArticleId><ArticleId IdType="pubmed">22499787</ArticleId></ArticleIdList></Reference><Reference><Citation>Aoki C, Hidari KI, Itonori S, Yamada A, Takahashi N, Kasama T, Hasebe F, Islam MA, Hatano K, Matsuoka K, Taki T, Guo CT, Takahashi T, Sakano Y, Suzuki T, Miyamoto D, Sugita M, Terunuma D, Morita K, Suzuki Y. Identification and characterization of carbohydrate molecules in mammalian cells recognized by dengue virus type 2. J Biochem. 2006;139:607&#x2013;614. doi: 10.1093/jb/mvj067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jb/mvj067</ArticleId><ArticleId IdType="pubmed">16567427</ArticleId></ArticleIdList></Reference><Reference><Citation>Midgley CM, Flanagan A, Tran HB, Dejnirattisai W, Chawansuntati K, Jumnainsong A, Wongwiwat W, Duangchinda T, Mongkolsapaya J, Grimes JM, Screaton GR. Structural analysis of a dengue cross-reactive antibody complexed with envelope domain III reveals the molecular basis of cross-reactivity. J Immunol. 2012;188:4971&#x2013;4979. doi: 10.4049/jimmunol.1200227.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1200227</ArticleId><ArticleId IdType="pmc">PMC3364712</ArticleId><ArticleId IdType="pubmed">22491255</ArticleId></ArticleIdList></Reference><Reference><Citation>Nybakken GE, Oliphant T, Johnson S, Burke S, Diamond MS, Fremont DH. Structural basis of West Nile virus neutralization by a therapeutic antibody. Nature. 2005;437:764&#x2013;769. doi: 10.1038/nature03956.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature03956</ArticleId><ArticleId IdType="pmc">PMC7095628</ArticleId><ArticleId IdType="pubmed">16193056</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JW, Chu JJ, Ng ML. Quantifying the specific binding between West Nile virus envelope domain III protein and the cellular receptor alphaVbeta3 integrin. J Biol Chem. 2006;281:1352&#x2013;1360. doi: 10.1074/jbc.M506614200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M506614200</ArticleId><ArticleId IdType="pubmed">16275649</ArticleId></ArticleIdList></Reference><Reference><Citation>Lisova O, Belkadi L, Bedouelle H. Direct and indirect interactions in the recognition between a cross-neutralizing antibody and the four serotypes of dengue virus. J Mol Recognit. 2014;27:205&#x2013;214. doi: 10.1002/jmr.2352.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmr.2352</ArticleId><ArticleId IdType="pubmed">24591178</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>